To define the cytokine and cellular immune signature of primary hypertension. Cross sectional clinical/laboratory study.
Experimental data show the presence of immune and inflammatory systems dysregulation in hypertension. Understanding of the inflammatory and immune nature of hypertension is currently based on studies in rodent models of hypertension, but is supported by human epidemiological and genome wide association studies (GWAS) studies. It is now essential to identify key checkpoints and inflammatory mechanism(s) involved in human hypertension in comprehensive and sufficiently powered studies, which will then be able to guide subsequent in-depth hypothesis-driven mechanistic studies. This approach may provide the basis for future randomized clinical trials (RCTs). To define the relationships and predictive value of the immune signature of hypertension and clinical phenotypes of hypertension : * Predictive value of immune signature for blood pressure parameters measured by ambulatory blood pressure measurements (ABPM) * Predictive value of immune signature for endothelial function assessed by Endo-PAT2000 and flow mediated dilatation (FMD) both complementary non-invasive techniques. * Predictive value of immune signature for vascular stiffness and central pressure assessed by SphygmoCor * Predictive value of immune signature for renal function parameters * Predictive value of immune signature for cognitive function. To define genetic determinants of immune signature of hypertension.
Study Type
OBSERVATIONAL
Enrollment
160
NO intervention
Clinical Research Facility
Glasgow, City of Glasgow, United Kingdom
RECRUITINGcellular immune signature of primary hypertension: flow cytometry quantification of peripheral blood monocyte subtypes
measuring expression of B cells markers, T cell markers, and DC cell markers
Time frame: rolling analysis until total number recruited or end of study period (June 2021)
demographics: blood pressure
systolic and diastolic; office and ambulatory; in mmHG
Time frame: rolling analysis until total number recruited or end of study period (June 2021)
demographics: BMI
in kg/m\^2; calculated from height in meters and weight in kg
Time frame: rolling analysis until total number recruited or end of study period (June 2021)
Endo-PAT2000 "hyperaemia index"
As a measure of endothelial function: measuring Peripheral Arterial Tone (PAT) signal changes to a reactive hyperemia challenge. The PAT signal is a measure of the digital pulsatile volume. The expected response is of a post occlusion increase of the PAT signal amplitude. PAT score is provided automatically by the system's software and is basically the ratio between the post- to pre- occlusion average signal size, corrected for systemic changes and baseline level. changes
Time frame: until total number recruited or end of study period (June 2021)
flow mediated dilatation (FMD) (percent)
as a measure of endothelial function
Time frame: until total number recruited or end of study period (June 2021)
carotid intimal media thickness (mm)
measure of vascular stiffness and central pressure
Time frame: until total number recruited or end of study period (June 2021)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
assessed by SphygmoCor (meters/second)
measure of vascular stiffness and central pressure
Time frame: until total number recruited or end of study period (June 2021)
serum Creatinine (mMol/L)
measure of renal function
Time frame: until total number recruited or end of study period (June 2021)
"International Physical Activity Questionnaire" (score)
Questionnaire measures of physical activity. From hours of sedentary time, mild/moderate/vigorous activity over a week, it then calculates METs/week.
Time frame: until end of study period (June 2021)
Interheart Diet Questionnaire score
Questionnaire measures of health and activity. Based on known risk factors ie smoking diabetes, family history, dietary factors. Used as a validated measure of cardiovascular risk; score from 0 (minimal risk) to 48 (high risk)
Time frame: until end of study period (June 2021)